touchIMMUNOLOGY caught up with Prof. Xenofon Baraliakos (Ruhr-University Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany) around his post hoc analysis using the HEMRIS system as a clinical endpoint in the ACHILLES study (NCT02771210).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Imaging Characteristics in Patients with Spondyloarthritis Using a Novel Heel Enthesitis Magnetic Resonance Imaging Scoring (HEMRIS) System: Post-hoc Analysis of a Phase 3 Secukinumab Trial.’ (ABSTRACT NUMBER: 0469) was presented at the ACR Convergence, 3-9 November 2021.
Questions
- Why is there a need for novel imaging biomarkers in spondyloarthritis (SpA)? (0:25)
- Could you give us an overview of the Heel Enthesitis MRI Scoring system (HEMRIS) and its use as a clinical endpoint in studies of SpA? (1:16)
- What were the aims and design of the post hoc analysis of the ACHILLES study? (2:34)
- What were the findings of the study? (3:03)
- What were the conclusions of the investigators regarding the future use of the HEMRIS system? (4:12)
Disclosures: Xenofon Baraliakos is a paid consultant for Novartis, who conducted the study.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual ACR Convergence 2021.
